Cargando…

Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients

BACKGROUND: The effects of sodium-glucose cotransporter 2 inhibitor (SGLT2i) on cardiac function are not fully understood. We investigated the changes in cardiac function in diabetic patients according to the presence and types of heart failure (HF). METHODS: We retrospectively identified 202 diabet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hwang, In-Chang, Cho, Goo-Yeong, Yoon, Yeonyee E., Park, Jin Joo, Park, Jun-Bean, Lee, Seung-Pyo, Kim, Hyung-Kwan, Kim, Yong-Jin, Sohn, Dae-Won
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254690/ https://www.ncbi.nlm.nih.gov/pubmed/32466760 http://dx.doi.org/10.1186/s12933-020-01042-3

Ejemplares similares

Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials
por: Hwang, In-Chang, et al.
Publicado: (2017)

Healthcare utilization, medical expenditure, and mortality in Korean patients with pulmonary hypertension
por: Hwang, In-Chang, et al.
Publicado: (2019)

Prognostic implications of left ventricular mass-geometry in patients with no or nonobstructive coronary artery disease
por: Choi, You-Jung, et al.
Publicado: (2021)

Long-term Effects of high-doSe pitavaStatin on Diabetogenicity in comparison with atorvastatin in patients with Metabolic syndrome (LESS-DM): study protocol for a randomized controlled trial
por: Park, Jun-Bean, et al.
Publicado: (2017)

Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fraction
por: Kim, Hyue Mee, et al.
Publicado: (2021)

Body Mass Index, Muscle Mass, and All-Cause Mortality in Patients With Acute Heart Failure: The Obesity Paradox Revisited
por: Hwang, In-Chang, et al.
Publicado: (2022)

Assessing Impact of High-Dose Pitavastatin on Carotid Artery Elasticity with Speckle-Tracking Strain Imaging
por: Kim, Chee Hae, et al.
Publicado: (2018)

Prognostic and Safety Implications of Renin-Angiotensin-Aldosterone System Inhibitors in Hypertrophic Cardiomyopathy: A Real-World Observation Over 2,000 Patients
por: Park, Chan Soon, et al.
Publicado: (2023)

The Incremental Prognostic Value of Cardiac Computed Tomography in Comparison with Single-Photon Emission Computed Tomography in Patients with Suspected Coronary Artery Disease
por: Lee, Heesun, et al.
Publicado: (2016)

Prediction of Deterioration of Left Ventricular Function Using 3‐Dimensional Speckle‐Tracking Echocardiography in Patients With Left Bundle‐Branch Block
por: Kim, Hyue Mee, et al.
Publicado: (2022)

Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction
por: Moon, Mi‐Gil, et al.
Publicado: (2021)

Echocardiographic Predictors for Left Ventricular Remodeling after Acute ST Elevation Myocardial Infarction with Low Risk Group: Speckle Tracking Analysis
por: Na, Hyun-Min, et al.
Publicado: (2016)

Prognostic Value of Renal Function for Cardiac Events in Patients Without Significant Stenosis on Coronary Computed Tomography Angiography
por: Kim, Hack-Lyoung, et al.
Publicado: (2015)

Left Atrial Mechanical Function and Global Strain in Hypertrophic Cardiomyopathy
por: Kim, Kyung-Jin, et al.
Publicado: (2016)

Association between Aspirin Therapy and Clinical Outcomes in Patients with Non-Obstructive Coronary Artery Disease: A Cohort Study
por: Hwang, In-Chang, et al.
Publicado: (2015)

Endocardial versus whole-myocardial tracking global longitudinal strain analysis in patients with hypertrophic cardiomyopathy: A preliminary comparative study
por: Park, Jiesuck, et al.
Publicado: (2023)

Phenotyping Heart Failure According to the Longitudinal Ejection Fraction Change: Myocardial Strain, Predictors, and Outcomes
por: Park, Jin Joo, et al.
Publicado: (2020)

Comparison of mortality and cause of death between adults with and without hypertrophic cardiomyopathy
por: Kwon, Soonil, et al.
Publicado: (2022)

Arterial stiffness, endothelial and cognitive function in subjects with type 2 diabetes in accordance with absence or presence of diabetic foot syndrome
por: Tuttolomondo, Antonino, et al.
Publicado: (2017)

Predictors of paravalvular aortic regurgitation after surgery for Behcet’s disease-related severe aortic regurgitation
por: Choi, Hong-Mi, et al.
Publicado: (2019)

Clinical implication of right-sided augmentation pressure in patients with pulmonary hypertension
por: Sohn, Dae-Won, et al.
Publicado: (2019)

Augmented risk of dementia in hypertrophic cardiomyopathy: A propensity score matching analysis using the nationwide cohort
por: Lee, Heesun, et al.
Publicado: (2022)

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis
por: McGuire, Darren K., et al.
Publicado: (2020)

External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease
por: Smidt, Lisanne C. A., et al.
Publicado: (2021)

Effect of Dipeptidyl Peptidase-4 Inhibitor on All-Cause Mortality and Coronary Revascularization in Diabetic Patients
por: Park, Hyo Eun, et al.
Publicado: (2015)

Effect of Moderately but Persistently Elevated Lipid Levels on Risks of Stroke and Myocardial Infarction in Young Korean Adults
por: Park, Jun‐Bean, et al.
Publicado: (2021)

Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes and Cardiovascular Disease
por: Luo, Jing, et al.
Publicado: (2023)

Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study
por: Kim, Young-Gun, et al.
Publicado: (2018)

SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs
por: Giugliano, Dario, et al.
Publicado: (2021)

Differential impact of metabolic syndrome on subclinical atherosclerosis according to the presence of diabetes
por: Won, Ki-Bum, et al.
Publicado: (2013)

Subclinical left ventricular diastolic dysfunction and incident type 2 diabetes risk: the Korean Genome and Epidemiology Study
por: Park, Juri, et al.
Publicado: (2017)

Differential diagnosis of common etiologies of left ventricular hypertrophy using a hybrid CNN-LSTM model
por: Hwang, In-Chang, et al.
Publicado: (2022)

Risk of end-stage renal disease in patients with hypertrophic cardiomyopathy: A nationwide population-based cohort study
por: Lee, Heesun, et al.
Publicado: (2019)

Left atrial remodeling and mechanical dysfunction in hypertrophic cardiomyopathy
por: Kim, Kyung-Jin, et al.
Publicado: (2016)

Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
por: Lin, Bowen, et al.
Publicado: (2014)

Contemporary Imaging Diagnosis of Cardiac Amyloidosis
por: Lee, Seung-Pyo, et al.
Publicado: (2019)

SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice
por: Lee, Dustin M., et al.
Publicado: (2018)

Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF
por: Bode, David, et al.
Publicado: (2021)

Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease
por: Lim, Jayoung, et al.
Publicado: (2022)

Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study
por: Seong, Jong-Mi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_equ0u46uv9ka43aon9t92u2443